Estrella Immunopharma (ESLA) has released an update.
Estrella Immunopharma, Inc. announced that its board of directors has approved a share repurchase program up to $1 million of its common stock. The repurchase is not an obligation and will depend on future market conditions and other factors, with details to be decided as those conditions evolve.
For further insights into ESLA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
